TFG::ALK fusion in ALK positive large B-cell lymphoma: a case report and review of literature
Anaplastic lymphoma kinase (ALK) positive large B-cell lymphoma (ALK+ LBCL) is an aggressive and rare subtype of B-cell lymphoma.Patients typically present with advanced clinical stage disease and do not respond to conventional chemotherapy; the median overall survival is 1.8 years.The genetic landscape of this entity remains poorly understood.Here